1. |
Is influenza vaccination feasible in healthy adults? |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
Pharma-sponsored DM: where to now? |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 3-4
Amanda Cameron,
Preview
|
|
摘要:
In the early, heady days of disease management (DM), pharmaceutical companies leapt into the area with high hopes of making profits that would rival those from their products. Today, few companies still provide DM services, and the 'prefab' DM programme has all but disappeared. Speaking at the 2nd Annual Disease Management Leadership Forum*[Baltimore, Maryland, US; November 2000], Mark Zitter, chairman of the Zitter Group, US, explained why DM still presents opportunities for the pharmaceutical industry, and what shape pharma industry's future involvement in DM is likely to take.
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Paediatric medication use high in The Netherlands |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
News in brief... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
Infectious disease service cuts costs, prescribing in ICU |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
Entacapone adjunctive therapy clear choice in Parkinson's disease |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 9-9
Laura Hunt,
Preview
|
|
摘要:
Approximately 50% of patients with Parkinson's disease experience 'off time' - abnormal involuntary movements associated with both levodopa therapy and the disease itself. Entacapone, a selective reversible inhibitor of catechol-O-methyltransferase, has been approved for use in the US and the European Union as adjunctive therapy to levodopa and carbidopa in patients with Parkinson's disease. Use of entacapone provides patients with immediate symptomatic relief and enables a 10-12% reduction in the dosage of levodopa. In addition, entacapone has been shown to significantly reduce 'off time' by 17-22%. A study evaluating the cost effectiveness of entacapone in patients with Parkinson's disease was presented at a poster session held at the ISPOR*3rd Annual European Conference [Antwerp, Belgium; November 2000], and is the focus of this report.
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
News in brief ... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
News in brief ... |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
Another drug price freeze in Brazil set for 2001 |
|
PharmacoEconomics & Outcomes News Weekly,
Volume &NA;,
Issue 297,
2001,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-5503
出版商:ADIS
年代:2001
数据来源: ADIS
|